Trinity Biotech plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Trinity Biotech plc
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
- In Vitro Diagnostics
- Diagnostic Equipment & Supplies
In Vitro Diagnostics
- Chemistry, Immunoassay
- Large Molecule
- Other Names / Subsidiaries
- Fiomi Diagnostics AB
- Fitzgerald Industries International
- Immco Diagnostics Inc.
- MarDx Diagnostics